Becaplermin (Regranex0), a cellular growth factor, is marketed in gel form in France for the treatment of chronic ulcerated lesions due to diabetic neuropathy (1,2).In late 2009, the European Medicines Agency published an analysis of its adverse effects, based on 17 clinical trials in a total of 1883 diabetic and non-diabetic patients. Becaplermin was used to treat ulceration, bed sores and venous ulcers.
展开▼
